ACCPL — Accretion Pharmaceuticals Balance Sheet
0.000.00%
- IN₹1.24bn
- IN₹1.32bn
- IN₹896.27m
Annual balance sheet for Accretion Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 3.75 | 0.364 | 0.916 | 0.508 | 40.2 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 45.7 | 66.6 | 68.5 | 128 | 279 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 119 | 145 | 216 | 335 | 606 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 58.4 | 60.1 | 52.7 | 60.9 | 134 |
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 177 | 206 | 270 | 399 | 767 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 117 | 138 | 147 | 232 | 208 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 147 | 167 | 217 | 246 | 219 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 30.8 | 38.4 | 53.5 | 153 | 547 |
| Total Liabilities & Shareholders' Equity | 177 | 206 | 270 | 399 | 767 |
| Total Common Shares Outstanding |